CDK9-IN-33

• UNSPSC Description:

  CDK9-IN-33 (compound C35) is a potent, selective and orally active CDK9 inhibitor with IC50 values of 17.44, 160, 316.30, 1771.00, >10000 nM for CDK9, CDK7, CDK2, CDK4, CDK6 respectively. CDK9-IN-33 induces apoptosis. CDK9-IN-33 decreases the protein expression of RPB1 CTD Ser2, RPB1, MCL1. CDK9-IN-33 shows anti-tumor activity[1].

• Target Antigen:

  Apoptosis; CDK

• Type:

  Reference compound

• Related Pathways:

  Apoptosis;Cell Cycle/DNA Damage

• Field of Research:

  Cancer

• Assay Protocol:

  https://www.medchemexpress.com/cdk9-in-33.html

• Smiles:

  CC(C1=C2N=C(N=C(N2N=C1)NCC3=CC=C(C=C3)NC(CC)=O)NC4CCOCC4)C

• Molecular Weight:

  437.54

• References & Citations:

  [1]Wang WJ, et al. Discovery of Orally Bioavailable and Potent CDK9 Inhibitors for Targeting Transcription Regulation in Triple-Negative Breast Cancer. J Med Chem. 2024 Jun 27;67(12):10035-10056.

• Shipping Conditions:

  Room temperature

• Clinical Information:

  No Development Reported